Methicillin-resistant Staphylococcus aureus and vancomycin: Minimum inhibitory concentration matters

Clinical Infectious Diseases

Volumn 54, Issue 6, 2012, Pages 772-774

  Deresinski, Stan ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTOBIPROLE; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; FOSFOMYCIN; FUSIDIC ACID; LINEZOLID; RIFAMPICIN; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; DRUG SENSITIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NOTE; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84857619579     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir932     Document Type: Note

References (22)

1. Mohr JF, Murray BE. Point: vancomycin is not obsolete in the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2007; 44:1536-42. (Pubitemid 46871498)
2. Deresinski S. Counterpoint: vancomycin and Staphylococcus aureus-an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543-8. (Pubitemid 46871499)
3. Deresinski S. Vancomycin: does it still have a role as an antistaphylococcal agent? Expert Rev Anti Infect Ther 2007; 5:393-401. (Pubitemid 47050161)
4. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925-42. (Pubitemid 39447034)
5. Moise PA, Sakoulas G, Forrest A, Schentag JJ. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007; 51:2582-6. (Pubitemid 47047340)
6. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis 2011; 52:975-81.
7. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano GL, Lodisie TP. Vancomycin: We can't get there from here. Clin Infect Dis 2011; 2:969-74.
8. Bosso JA, Nappi J, Rudisill C, et al. Relationship between trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 2011; 55:5475-9.
9. van Hal SJ, Barbagiannakos T, Jones M, et al. Methicillin-resistant Staphylococcus aureus vancomycin susceptibility testing: methodology correlations, temporal trends and clonal patterns. J Antimicrob Chemother 2011; 66:2284-7.
10. van Hal SJ, Lodise TI, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentrations in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012; 54:755-71.
11. Richter SS, Satola SW, Crispel EK, et al. Detection of Staphylococcus aureus with heterogeneous intermediate-level resistance to vancomycin (hVISA) in the United States. J Clin Microbiol 2011; 49:4203-7.
12. Deresinski S. Vancomycin heteroresistance and methicillin-resistant Staphylococcus aureus. J Infect Dis 2009; 199:605-9.
13. Khatib R, Jose J, Musta A, et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillinresistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011; 66:1594-9.
14. Satola SW, Lessa FC, Ray SM, et al. Active Bacterial Core Surveillance MRSA Investigators. Clinical and laboratory characteristics of invasive infections due to methicillinresistant Staphylocccus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. aureus phenotype. J Clin Microbiol 2011; 49:1583-7.
15. van Hal SJ, Jones M, Gosbell IB, Paterson DL. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillinresistant Staphylococcus aureus blood stream infections. PLoS One 2011; 6:e21217.
16. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:385-92.
17. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166:2138-44. (Pubitemid 44631403)
18. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC, et al. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann Pharmacother 2011; 45:757-63.
19. Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis 2007; 45: S177-83. (Pubitemid 47378904)
20. Deresinski S. Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2009; 49: 1072-9.
21. Seah J, Lye D, Ng T, et al. Add-on combination therapy to vancomycin not better for persistent MRSA bacteremia [abstract K-885/379]. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Illinois: American Society for Microbiology, 2011.
22. Moore CL, Osaki-Kiyan P, Haque NZ, et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012; 54:51-8.